In line with attenuated cardiac hypertrophy, AAV-Drp1i and AAV-Mfn1 treatment reduced the ratio of heart weight to tibia length, heart weight to body weight, and hypertrophy markers expression 10 weeks after icKO (Figure 7G and 7H; Figure S17B). Here, MFN1 is linked to cardiac hypertrophy.